Literature DB >> 7519659

Altered brain metabolism of iron as a cause of neurodegenerative diseases?

M Gerlach1, D Ben-Shachar, P Riederer, M B Youdim.   

Abstract

Iron is the most abundant metal in the human body (Pollitt and Leibel, 1982; Youdim, 1988), and the brain, like the liver, contains a substantially higher concentration of iron than of any other metal (Yehuda and Youdim, 1988). Within the brain, iron shows an uneven distribution, with high levels in the basal ganglia (substantia nigra, putamen, caudate nucleus, and globus pallidus), red nucleus, and dentate nucleus (Spatz, 1922; Hallgren and Sourander, 1958; Hill and Switzer, 1984; Riederer et al., 1989). Iron deposition in the brain is mainly in organic storage forms such as ferritin but not hemosiderin (Hallgren and Sourander, 1958; Octave et al., 1983), with relatively little in a free and reactive form. Although the function of a regionally high brain iron content is unknown, the homeostasis of brain iron is thought to be necessary for normal brain function, especially in learning and memory (Youdim et al., 1989; Yehuda and Youdim, 1989; Pollit and Metallinos-Katsaras, 1990; Youdim, 1990). Thus, a high content of brain iron may be essential, particularly during development, but its presence means that injury to brain cells may release iron ions that can lead to oxidative stress via formation of oxygen free radicals. Such radicals are thought to be involved in lipid peroxidation of the cell membrane, leading to increased membrane fluidity, disturbance of calcium homeostasis, and finally cell death (Youdim et al., 1989; Halliwell, 1992). Iron is an essential participant in many metabolic processes, including (a) DNA, RNA, and protein synthesis, (b) as a cofactor of many heme and nonheme enzymes, (c) the formation of myelin, and (d) the development of the neuronal dendritic tree (Ben-Shachar et al., 1986; Youdim et al., 1991b). A deficiency of iron metabolism would therefore be expected to alter some or all of these processes (Jacobs and Worwood, 1980; Youdim, 1985, 1988). Studies of iron distribution in the human brain have demonstrated that the degree of iron deposition, primarily in the basal ganglia (a predominantly dopamine structure), increases with age (Hallgren and Sourander, 1958) and in certain disorders, most notably the basal ganglia disorders (Seitelberger, 1964). This review will present some of the experimental evidence indicating a role of disturbed iron metabolism as a cause of the neurodegenerative disorder Parkinson's disease and possibly other neurodegenerative disorders such as Alzheimer's disease.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519659     DOI: 10.1046/j.1471-4159.1994.63030793.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  147 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance.

Authors:  V Calabrese; T E Bates; A M Stella
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

3.  Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.

Authors:  Moussa B.H. Youdim; Edna Grünblatt; Yona Levites; Gila Maor; Silvia Mandel
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

4.  Nramp1 is expressed in neurons and is associated with behavioural and immune responses to stress.

Authors:  C A Evans; M S Harbuz; T Ostenfeld; A Norrish; J M Blackwell
Journal:  Neurogenetics       Date:  2001-03       Impact factor: 2.660

Review 5.  Innovative techniques and applications in histochemistry and cell biology.

Authors:  Esther Asan
Journal:  Histochem Cell Biol       Date:  2003-11-28       Impact factor: 4.304

6.  Perfusion-Perls and -Turnbull methods supplemented by DAB intensification for nonheme iron histochemistry: demonstration of the superior sensitivity of the methods in the liver, spleen, and stomach of the rat.

Authors:  Reiko Meguro; Yoshiya Asano; Hiroyasu Iwatsuki; Kazuhiko Shoumura
Journal:  Histochem Cell Biol       Date:  2003-06-12       Impact factor: 4.304

7.  Accumulation of non-transferrin-bound iron by neurons, astrocytes, and microglia.

Authors:  Glenda M Bishop; Theresa N Dang; Ralf Dringen; Stephen R Robinson
Journal:  Neurotox Res       Date:  2010-04-30       Impact factor: 3.911

Review 8.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

9.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

10.  Cell-cycle arrest and inhibition of G1 cyclin translation by iron in AFT1-1(up) yeast.

Authors:  C C Philpott; J Rashford; Y Yamaguchi-Iwai; T A Rouault; A Dancis; R D Klausner
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.